<div><strong>Twenty-one children. A rare disease. A real chance. </strong>
</div>
<div><br />
</div>
<div>Sophia Ibrahim (9), Emil (7), Mary (13) and Neveah (10), Jonathan (9), Charnice (4) and Madison (3) – five lovely and joyful kids from Australia, the United States, South Africa, UK and Germany. What do they have in common? A very rare genetic disorder: PGAP1-CDG.
</div>
<div><br />
</div>
<div>They can’t speak, walking is difficult or impossible for some, and many things are only possible with support. And yet – they laugh, play, cuddle – and their families fight for them every single day.
</div>
<div><br />
</div>
<div>“Worldwide, only 21 children are known to be affected by this gene defect,” say the geneticists, “with odds of around 1 in 21 million.”
</div>
<div><strong>But now, there is hope.</strong>
</div>
<div>________________________________________
</div>
<div><strong>A Breakthrough in Sight – We Need You!</strong>
</div>
<div><br />
</div>
<div>Researchers at the renowned Children’s Medical Research Institute (CMRI) in Sydney have identified a small molecule that can stimulate the function of the defective PGAP1 gene. "Initial lab tests are promising: It works", says Leszek Lisowski, head of the research Programme. "Now, the molecule is to be tested on disease models built using cells of affected children – a crucial next step towards a therapy." In fact, the last step required to initiate clinical studies.
</div>
<div><br />
</div>
<div><strong>"We are very close and all kids affected by this ultrarare disease will be able to benefit from the results!"</strong>
</div>
<div><br />
</div>
<div>To make this happen, we parents have built an international cooperation with the Department of Pediatric and Adolescent Medicine of the University Clinic Göttingen - UMG. “We see great potential in this new medical approach”, says Dr. Christin Johnsen, doctor at the UMG.
</div>
<div><br />
</div>
<div><strong>Everything is ready – we only need a few more funds to finance these last steps on the way to a therapeutic breakthrough.</strong>
</div>
<div>________________________________________
</div>
<div><strong>Why We Depend on Private Support</strong>
</div>
<div><br />
</div>
<div>Ultra-rare diseases are often “not profitable” for the pharmaceutical industry. That’s why there is no public funding, no support from healthcare companies.
</div>
<div><br />
</div>
<div>Nevertheless, we have a very realistic chance to substantially improve the lives of our kids and all other affected kids with this breakthrough research, if not cure the disease at all.
</div>
<div><br />
</div>
<div>Us parents have already invested a lot of our own money – but now we can’t do it alone anymore.
</div>
<div>________________________________________
</div>
<div><strong>Help Us Turn Hope Into Reality</strong>
</div>
<div><br />
</div>
<div>We urgently need USD 100,000 to conduct the next tests and bring the therapy into clinical trial for our kids.
</div>
<div><br />
</div>
<div>Every single cent goes directly to the research at CMRI in Sydney and the implementation of the therapeutic approach.
</div>
<div>________________________________________
</div>
<div><strong>How You Can Help – Every Donation Matters!</strong>
</div>
<div><br />
</div>
<div>Whether it’s USD 10, 50, 100, or 500 – every contribution brings us closer to making a therapy possible for our children. Together, we can make it happen!
</div>
<div><br />
</div>
<div>All gifts will support (gene) therapy research into PGAP1 led by Children’s Medical Research Institute, including ancillary costs – such as salary and salary on-costs, and research and project costs including laboratory materials, samples, consumables and equipment. 100% of the donations will be used for this critical research. <strong>No administrative fees </strong>are taken by Children’s Medical Research Institute.
</div>
<div><br />
</div>
<div><strong>We’ve already come a long way – but we can’t move forward without you.</strong>
</div>
<div>________________________________________
</div>
<div><strong>Our Appeal to You</strong>
</div>
<div><br />
</div>
<div>Help us give Emil, Mary, Jonathan, Charnice and Madison, as well as all other PGAP1 kids a real future.
</div>
<div><br />
</div>
<div>A future with more possibilities, more inclusion – more life.
</div>
<div><br />
</div>
<div><strong>Be part of this story. Donate now.</strong>
</div>
<div><br />
</div>
<div><strong>watch our youtube explainer on PGAP1: </strong><a href="https://youtu.be/OMOYnh690VU" target="_blank" rel="noreferrer noopener"><a href="https://youtu.be/OMOYnh690VU" target="_blank" class="" rel="nofollow noopener noreferrer">https://youtu.be/OMOYnh690VU</a></a>
</div>

Sevval Begun

Shelly Johnston

Sergio Oliva

Anna Maria I.

Anonymous

Chandu Rama

Santosh Gupta

Sharmayne Sargent

Lisa Lalor

Brittney W

Lan Anh Phan

Eddy Harb

Support Breakthrough Therapy for Kids with ultrarare Disease

platform

Platform is iOS

Android

Adyen Google Pay Development Audience

$opt_dummy_attribute

English only

Deprecate Stripe Legacy

dyn_template_ids

Adyen V6 Bene Transfer & MyMoney Campaign Organizers - test01

Bene transfer V6 and AdyenV6MyMoney Campaign Organizers - production

OneTrust next-app audience

fundCountryCode

NextDoor Share Option Users

Fundraisers with Reactions feature capability

fundCurrencyCode

US + Non-charity COs Only

locale

fund country is US and user language is English

personId

comms-internal-person-ids

Enhanced Story Experience Users

Suggested Goal Experience Users

user language is English and fund country: US, AU, DK, FI, IE, NO, SE, CA, GB; 

Poster share - new funds eligible (newest 9/18)

Streaming widgets beta user

paymentProcessor

3DS payment method

user language is English and fundCountry: US, AU, DK, FI, IE, NO, SE, CA, GB; 

GoFundMe Employees

ipAddress

Mark Rieth IP Address

Version 9.2.0 and above

Fund is in English speaking country

desktop

Android v12.11.0 and above

Platform is Android

paymentMethodType

checkoutType

Payment method type group to be vaulted on success

admin pr kit prod

EUR Donation Upsell

Share Text generation Skip Fundraiser

(prod) new funds eligible for amp12 (UGC gallery)

fintrac_cad_idv_form_v2 audience

paymentProcessorAccountId

fallback mode accounts

proCampaignId

p2p legacy startfundraising page

AMP24 New Funds Only PROD (DO NOT MODIFY)

countryCode

charityId

UKCharities

Federated Search Internal Testing

route.pathname community

US Donation Upsell audience 

Auto Thanks Feature Audience

Supporter Comments Eligible Funds

International Only

fundId

braze fundraiser group 

Payment Identity Transfers ATO Risk Check (Targeted) - Production

Fundraiser Saved Payment Method Rate Limit Bypass (Production)

leaderboard-partner-id-audience-givepanel

Version 9.2.1 and above

AUD Donation Upsell audience

fundraiserCountryCode is US/EN

Active Fundraiser - Smart Default Cadence

DAF Internal

Vault on success card payment method

Platform is iOS v11.0.0 and above

Desktop users

Person ids

United States (US) users

allow yuno fundraisers for test

Mexico country code

Posters INTL

NPO Profile Opted-In

iOS at or above 12.4.0

non-US recurring donors

Canada Campaign Owner Group

Fundraiser Without Meta Link

Scheduler payment tester gorup

charityCommunityId

Charities allow to be claimed unclaimed (PRD)

Canada (CA) users

currencyCode

UC Tipping v20250115 International

pymk_production_xplr_fe_team

Android at or above 12.2.0

Profile photo entry point audience

smart goals (fundraiser/manage) on test01

Activity Tracking v1 Beta Testing

writePath

Stream Notification

start gfm intl allowed locales

Platform is iOS v11.2.0 and above

unclaimed charities

prod_ach_audience

AI Chatbot Audience

amp13 only new funds (prod) (anyword auto)

UC Flow Enabled (Prod)

Payment Identity Beneficiary Verification - Production

shared notification bell audience

Custom users

ach frontend audience

Android v11.0.0 and above

Users Receiving Payments Paused Notifications

smart goals test01

Manage Coach - US English Organizers Only + new funds only

Team EGG - IP Address list

Fundraiser Without Instagram Deep Link

Native 11.4.0 and above

UC Tipping v20250107

Users Receiving Braze KYC Validation Failed

Native 11.3.0 and above

Influencer - Prod

US fundraisers and US users

ai_title_page

anyword

openai

control

manual_entry

userEmail

template_id

userId

fundUrl

isCharityCo

email

appVersion

shouldBucketIntoExperiment

partnerId

donationCadence

isActiveFundraiser

isPartner

isMobile

npoProfileOptIn

fundIsLinkedWithMeta

hasSessionDonation

isCampaignOwner

fundHasInstagramDeepLink

Native 11.4.0 and higher

New funds eligible - Video Sharing (PROD)

GB Donation Upsell audience 

Auto Thanks V3 Rollout Audience

Thank you V3 testing whitelist

isRecurringFriendly

Is Recurring Friendly

Excluded funds - Video Sharing

Logged In Users

CH Donation Upsell audience

Android v10.6.0 and above

userCurrencyCode

Localized Currency

v11.5.0 and above

testAudience

pathname

Survicate

appVersion is at or above 12.8.0

Non-charity fund

isChallengeFundraiser

challenge-fundraisers

Payment Identity Launch Verification - Production

New funds eligible - Posters v2

CAD Donation Upsell Audience

Braze Email Tester

NPO Profile Opted-Out

iOS App Version

hasKnownDonors

PYMK has donors

iOS v12.3.0 and above

Support Breakthrough Therapy for Kids with ultrarare Disease

Still $117,529 to go. Help us build momentum.